Cardinal Health, the second largest drug distributor in the US, is reported to be actively seeking a buyer for its China drug operations, with bids expected between $1.2 billion and $1.5 billion, according to sources. Shanghai Pharma, China Resources Pharma and Sinopharm are rumored to be suitors for Cardinal China, a significant PRC drug/device distributor. In 2010, Cardinal established a foothold in China with its $470 million purchase of ZuelligPharma, a company that in-licensed China/Asia rights to western drugs.
Source: ChinaBio Today
